TC
RNA

Trium Capital’s Atrium Therapeutics RNA Stock Holding History

Trium Capital’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
+113,278
New +$1.48M 0.94% 20

Other funds holding RNA

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Trium Capital's RNA Position: Q2 2026 in Review

Trium Capital opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 113,278 shares worth $1.52M. The stake represents 0.94% of the portfolio and ranks #20 among its holdings.

8 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Trium Capital held 113,278 shares of Atrium Therapeutics worth $1.52M as of Q2 2026.
  • Atrium Therapeutics was a new Trium Capital position in Q2 2026.
  • Atrium Therapeutics made up 0.94% of Trium Capital's portfolio in Q2 2026, its #20 holding.
  • 8 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Trium Capital's 13F filing for Q2 2026, filed 16 Jul 2026.